HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on CG Oncology (NASDAQ:CGON) and maintained a $75 price target.
May 10, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating and a $75 price target for CG Oncology, indicating a positive outlook on the stock.
The reiteration of a Buy rating and a maintained price target of $75 by a reputable analyst firm like HC Wainwright & Co. suggests a strong conviction in CG Oncology's potential. This endorsement is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100